Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
MeiraGTx Holdings plc - Ordinary Shares
(NQ:
MGTX
)
11.62
+0.14 (+1.22%)
Streaming Delayed Price
Updated: 11:20 AM EDT, Jun 23, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about MeiraGTx Holdings plc - Ordinary Shares
< Previous
1
2
Next >
MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 14, 2026
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Reports First Quarter 2026 Financial and Operational Results
May 14, 2026
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares
April 16, 2026
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)
April 16, 2026
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia
April 16, 2026
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026
April 14, 2026
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results
March 26, 2026
From
MeiraGTx
Via
GlobeNewswire
Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
February 17, 2026
Via
Investor Brand Network
Topics
Intellectual Property
Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
February 17, 2026
From
BioMedWire
Via
GlobeNewswire
MeiraGTx Reports Third Quarter 2025 Financial and Operational Results
November 13, 2025
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology
November 10, 2025
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress
October 07, 2025
Multiple Posters Highlight the Breadth of Company’s Novel Genetic Medicine and Cell Therapy Platforms
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Reports Second Quarter 2025 Financial and Operational Results
August 14, 2025
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting
May 13, 2025
Multiple Poster Presentations Highlight the Depth and Novelty of MeiraGTx’s Technology Platforms for Gene and Cell Therapy
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Reports First Quarter 2025 Financial and Operational Results
May 13, 2025
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s Disease
May 09, 2025
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates
March 13, 2025
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson’s Disease and Industrialize MeiraGTx’s Proprietary Manufacturing Process
March 13, 2025
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy
February 21, 2025
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations
January 22, 2025
MeiraGTx has recently received Rare Pediatric Disease Designation (RPDD) for four inherited retinal diseases (IRDs) reflecting the transformative therapeutic potential of the Company’s proprietary...
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia
December 09, 2024
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Announces Third Quarter 2024 Financial and Operational Results and Recent Business Updates
November 13, 2024
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Announces Five Posters at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress
October 22, 2024
Multiple Posters Highlight the Breadth of Company’s Novel Genetic Medicine and Cell Therapy Platforms
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Announces Positive Data from Randomized, Sham-controlled Clinical Bridging Study of AAV-GAD for the Treatment of Parkinson’s Disease
October 15, 2024
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Announces Poster Presentation on a Potential Treatment for MC4R Genetic Deficiency at the 2024 Society for Neuroscience Conference
October 09, 2024
Results indicate a potent and effective locally delivered AAV-BDNF gene therapy for the treatment of obesity caused by MC4R deficiency
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter 2024 Financial and Operational Results
August 12, 2024
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Announces Pricing of Offering of Ordinary Shares Led by Sanofi
August 12, 2024
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Reports First Quarter 2024 Financial and Operational Results
May 09, 2024
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx to Participate in Upcoming Investor Conferences
April 24, 2024
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conference
April 18, 2024
From
MeiraGTx
Via
GlobeNewswire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
